A new therapy uses only light and sound flickering at 40 hertz — and it prompts the brain to clear Alzheimer's plaques. MIT researchers have shown that this non-invasive sensory stimulation activates the brain's immune cells, reduces toxic protein build-up, and slows cognitive decline with virtually no side effects.
For educational purposes only — not medical advice. How we evaluate evidence →
Written by
Coeheal Editorial Team
Coeheal Editorial Team
Reviewed by
Editorially reviewed for accuracy against cited sources by the Coeheal editorial team, October 2026. This is an editorial review, not a medical or clinical review. For personalised health advice, consult a qualified healthcare professional.
Editorially reviewed for accuracy against cited sources.
Last reviewed
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Our editorial standards →
What if one of the most promising treatments for Alzheimer's disease required no drugs, no surgery, and no hospital visit — just lights flickering and sounds clicking at a precise frequency? That is exactly what researchers at the Massachusetts Institute of Technology (MIT) have been investigating, and the early results are striking enough to have attracted serious scientific attention worldwide.
The Science Behind 40Hz Stimulation. The therapy is built around a specific frequency: 40 hertz, or 40 cycles per second. This corresponds to gamma brainwaves — the high-frequency oscillations that the brain naturally produces during focused attention, memory consolidation, and cognitive processing. In Alzheimer's disease, gamma oscillations are disrupted. The brain's neural networks lose their synchrony, and this disruption appears to be both a symptom and a driver of the disease's progression. The MIT team, led by neuroscientist Li-Huei Tsai, asked a simple but profound question: what happens if you restore that 40Hz rhythm from the outside, using sensory stimulation?
How the Treatment Works. Patients are exposed to lights flickering at exactly 40 times per second — a frequency imperceptible as flicker to the naked eye but detectable by the brain's visual processing systems. Simultaneously, they hear sounds clicking at the same 40Hz rate. This combined audiovisual stimulation entrains the brain's gamma oscillations, nudging neural networks back toward their natural synchronous rhythm. The treatment sessions in clinical trials have typically lasted one hour per day.
The Immune Response: Microglia in Action. The most remarkable finding is what happens at the cellular level. The 40Hz stimulation appears to activate microglia — the brain's resident immune cells — into a more active, clearance-oriented state. Microglia are responsible for removing cellular debris, including the amyloid-beta plaques and tau tangles that accumulate in Alzheimer's disease and are strongly associated with neuronal death. In animal studies, gamma stimulation produced a measurable reduction in amyloid-beta levels within hours. The microglia were, in effect, prompted to do their housekeeping job more efficiently. This mechanism — using sensory input to modulate the brain's own immune response — is genuinely novel in neuroscience.
Clinical Trial Results. The landmark human study, published in PLOS ONE by Chan, Suk, Jackson, Milman, Stark, Klerman, and Tsai, examined patients with mild probable Alzheimer's disease. The findings were encouraging on multiple fronts. Beyond the reduction in amyloid burden, the therapy was associated with reduced brain atrophy — meaning the treatment appeared to slow the structural shrinkage of brain tissue that characterises Alzheimer's progression. Synaptic connections, which are essential for memory and cognition and are progressively destroyed in Alzheimer's, were better preserved in treated patients. The rate of cognitive decline was measurably slowed compared to controls.
The Safety Profile: A Genuine Advantage. One of the most significant aspects of this therapy is what it does not do. Because it relies entirely on non-invasive sensory stimulation — light and sound delivered through a device patients can use at home — it carries virtually no side effects. There are no drug interactions, no systemic toxicity, no risk of the brain swelling and microbleeds associated with the recently approved amyloid-targeting antibody drugs (lecanemab and donanemab). For patients and families who have watched loved ones decline through Alzheimer's, the prospect of a daily one-hour home treatment with no meaningful side effects is not a small thing.
Where the Research Stands. It is important to be honest about what the current evidence does and does not show. The clinical trials to date have been relatively small and focused on mild Alzheimer's. The therapy has not yet been shown to reverse established dementia or restore lost cognitive function — the evidence is for slowing progression, not reversal. Larger, longer trials are underway. The MIT team has founded a company, Cognito Therapeutics, to develop a commercial device (the Flicker device), which has received FDA Breakthrough Device designation — a designation that accelerates review for devices addressing serious conditions with unmet medical needs. This designation reflects the FDA's assessment that the early evidence is promising enough to warrant expedited evaluation.
For families navigating an Alzheimer's diagnosis, the honest message is this: 40Hz gamma stimulation is one of the most biologically plausible and safety-favourable interventions currently in the research pipeline. It is not yet an approved treatment. It is not a cure. But the mechanism is sound, the early human data is encouraging, and the risk profile is genuinely favourable compared to pharmaceutical alternatives. Some families are already using consumer-grade flickering light devices based on this research. If you are considering this, discuss it with a neurologist. The evidence does not yet support it as a replacement for any established care, but as a low-risk adjunct, the risk-benefit calculation is increasingly reasonable.
The Broader Significance. What makes this research genuinely exciting is not just the specific therapy — it is what it reveals about the brain's plasticity and the relationship between sensory input and neural health. The idea that you can modulate the brain's immune function, reduce toxic protein accumulation, and slow neurodegeneration through precisely calibrated sensory stimulation represents a fundamentally new way of thinking about brain disease. If the larger trials confirm what the early data suggests, 40Hz gamma stimulation could become the first widely accessible, home-based, non-pharmacological intervention with meaningful disease-modifying effects in Alzheimer's. That would be a genuine revolution in neurodegenerative care.
Source: Chan, D., Suk, H. J., Jackson, B. L., Milman, N. P., Stark, D., Klerman, E. B., & Tsai, L. H. Gamma frequency sensory stimulation in mild probable Alzheimer's disease patients. PLOS ONE.
Personalised plan
Get a personalised brain health and cognitive care plan.
Seen a claim you want to verify?
The Claim Decoder grades the evidence behind any natural health claim — A to F, with sources.
Suggested from this article:
"Lion's mane mushroom stimulates nerve growth factor in humans"
Prompted by: 40Hz Light and Sound Therapy: How MIT's Gamma Stimulation Clears Alzheimer's Plaques
The MIND diet reduces Alzheimer's risk by up to 53% in adherent individuals. Here is what the evidence says about food, brain aging, and cognitive decline — and the practical eating pattern that protects the most.
Omega-3s, lion's mane, phosphatidylserine, B vitamins, and vitamin D all have research behind them for cognitive health. Here is an honest look at what the evidence actually supports — and what it does not.
Regular aerobic exercise reduces dementia risk by 30–40% in large cohort studies. A landmark twin study found leg-focused resistance training produced a 47% improvement in cognitive performance. It also grows the hippocampus, increases BDNF, and clears amyloid. Here is the evidence — and the minimum effective dose.
